Tirzepatide
SURMOUNT-CN
Eli Lilly · Phase 3 · Completed · Enrollment 210
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| 10 Milligrams (mg) Tirzepatide | n/r | n/r | n/r | n/r | n/r |
| 15 mg Tirzepatide | 23 participants | 14 participants | 29 participants | n/r | 0 |
| Placebo | 4 participants | 3 participants | 6 participants | n/r | 0 |
| 10 mg Tirzepatide | 21 participants | 8 participants | 28 participants | n/r | 0 |
A count stays a count. This page does not turn a count into a percent.